## Maximilian Diehn

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8153962/maximilian-diehn-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150 215 22,755 59 h-index g-index citations papers 6.67 30,693 230 9.7 L-index avg, IF ext. papers ext. citations

#	Paper	IF	Citations
215	Inferring gene expression from cell-free DNA fragmentation profiles Nature Biotechnology, 2022,	44.5	5
214	Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. <i>Cancers</i> , <b>2022</b> , 14, 2479	6.6	1
213	Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis. <i>Blood</i> , <b>2021</b> , 138, 709-709	2.2	Ο
212	Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 6-6	2.2	4
211	Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing. <i>Blood</i> , <b>2021</b> , 138, 37-37	2.2	
210	Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. <i>Cancer Discovery</i> , <b>2021</b> ,	24.4	6
209	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. <i>Oncologist</i> , <b>2021</b> , 26, 523-532	5.7	1
208	Global analysis of shared Titell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. <i>Immunity</i> , <b>2021</b> , 54, 586-602.e8	32.3	16
207	Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1736-1753	24.4	14
206	Phased variants improve DLBCL minimal residual disease detection at the end of therapy <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 7565-7565	2.2	1
205	Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 8518-8518	2.2	1
204	Noninvasive identification of emergent mutations following cytotoxic therapy for lung cancer Journal of Clinical Oncology, <b>2021</b> , 39, 8533-8533	2.2	O
203	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 1030-1041	8.9	26
202	Detection and Diagnostic Utilization of Cellular and Cell-Free Tumor DNA. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2021</b> , 16, 199-222	34	4
201	Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. Journal of Thoracic Oncology, 2021, 16, 395-	-490.3	9
200	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , <b>2021</b> ,	44.5	16
199	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2605-2616	2.2	4

## (2020-2021)

198	Radiological tumor classification across imaging modality and histology. <i>Nature Machine Intelligence</i> , <b>2021</b> , 3, 787-798	22.5	9
197	A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 2016-2025	6.1	1
196	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. <i>Cancer Cell</i> , <b>2021</b> , 39, 1422-1437.e10	24.3	15
195	Atlas of clinically distinct cell states and ecosystems across human solid tumors. <i>Cell</i> , <b>2021</b> , 184, 5482-5	4 <b>96.æ</b> 2	.8 <sub>21</sub>
194	Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, e673-e677	4.9	0
193	Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2021</b> , 44, 559-564	2.7	2
192	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 1647-1662	8.9	48
191	A mathematical model of ctDNA shedding predicts tumor detection size. <i>Science Advances</i> , <b>2020</b> , 6,	14.3	36
190	A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk. <i>Genome Biology</i> , <b>2020</b> , 21, 107	18.3	11
189	Response Letter: Radiation therapy for COVID-19 pneumopathy. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 149, 238-239	5.3	2
188	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , <b>2020</b> , 580, 245-251	50.4	147
187	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , <b>2020</b> , 17, 757-770	19.4	82
186	Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. <i>Nature Cancer</i> , <b>2020</b> , 1, 176-183	15.4	71
185	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 650-659	13.4	297
184	Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA). <i>Blood</i> , <b>2020</b> , 136, 49-50	2.2	1
183	Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage. <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	1
182	Mechanisms and Markers of Clinical Radioresistance. Cancer Drug Discovery and Development, 2020, 63-	<b>96</b> .3	1
181	Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. <i>Gastroenterology</i> , <b>2020</b> , 158, 494-505.e6	13.3	71

180	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 274-281	12.9	49
179	Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , <b>2020</b> , 10, 1826-1841	24.4	26
178	Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer. <i>Theranostics</i> , <b>2020</b> , 10, 11707-1	1718	11
177	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , <b>2020</b> , 183, 363-376.e13	56.2	76
176	Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6176-6186	12.9	6
175	Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. <i>Nature Communications</i> , <b>2020</b> , 11, 6410	17.4	21
174	Stem Cells, Cell Differentiation, and Cancer <b>2020</b> , 97-107.e5		2
173	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2849-2858	12.9	36
172	FLT-PET-CT for the Detection of Disease Recurrence After Stereotactic Ablative Radiotherapy or Hyperfractionation for Thoracic Malignancy: A Prospective Pilot Study. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 467	5.3	4
171	Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. <i>Lung Cancer</i> , <b>2019</b> , 134, 42-45	5.9	19
170	Increases in Serial Pretreatment F-FDG PET-CT Metrics Predict Survival in Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy. <i>Advances in Radiation Oncology</i> , <b>2019</b> , 4, 429-437	3.3	1
169	Determining cell type abundance and expression from bulk tissues with digital cytometry. <i>Nature Biotechnology</i> , <b>2019</b> , 37, 773-782	44.5	761
168	Reply to J. Wang et al. Journal of Clinical Oncology, 2019, 37, 755-757	2.2	1
167	SABR-COMET: harbinger of a new cancer treatment paradigm. <i>Lancet, The</i> , <b>2019</b> , 393, 2013-2014	40	10
166	Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 461-468.e2	4.9	4
165	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , <b>2019</b> , 178, 699-713.e19	56.2	84
164	Predicting HLA class II antigen presentation through integrated deep learning. <i>Nature Biotechnology</i> , <b>2019</b> , 37, 1332-1343	44.5	112
163	Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy. <i>Blood</i> , <b>2019</b> , 134, 550-550	2.2	9

#### (2018-2019)

162	An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 655-655	2.2	4
161	Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA. <i>Blood</i> , <b>2019</b> , 134, 552-552	2.2	5
160	Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL. <i>Blood</i> , <b>2019</b> , 134, 1600-1600	2.2	2
159	Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling. <i>Blood</i> , <b>2019</b> , 134, 551-551	2.2	6
158	Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 491-491	2.2	
157	Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies. <i>Blood</i> , <b>2019</b> , 134, 885-885	2.2	
156	Deep segmentation networks predict survival of non-small cell lung cancer. <i>Scientific Reports</i> , <b>2019</b> , 9, 17286	4.9	32
155	Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. <i>Anti-Cancer Drugs</i> , <b>2019</b> , 30, 537-541	2.4	25
154	Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. <i>Nature Communications</i> , <b>2019</b> , 10, 5712	17.4	15
153	Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. <i>Cancer Discovery</i> , <b>2019</b> , 9, 500-50	094.4	75
152	A Feasibility Study of Single-inhalation, Single-energy Xenon-enhanced CT for High-resolution Imaging of Regional Lung Ventilation in Humans. <i>Academic Radiology</i> , <b>2019</b> , 26, 38-49	4.3	1
151	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2018</b> , 142, 1242-1253	5	72
150	Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2688-2699	12.9	32
149	F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 1183-1192	4	17
148	Genomic Feature Selection by Coverage Design Optimization. <i>Journal of Applied Statistics</i> , <b>2018</b> , 45, 26	5&-267	61
147	Endothelial deletion of Ino80 disrupts coronary angiogenesis and causes congenital heart disease. <i>Nature Communications</i> , <b>2018</b> , 9, 368	17.4	30
146	A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 1098-1106	4	15
145	Circulating tumor DNA testing in advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2018</b> , 119, 42-47	5.9	16

144	Deactivated CRISPR Associated Protein 9 for Minor-Allele Enrichment in Cell-Free DNA. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 307-316	5.5	19
143	Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer. <i>Lung Cancer</i> , <b>2018</b> , 124, 76-85	5.9	2
142	Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling. <i>Blood</i> , <b>2018</b> , 132, 672-672	2.2	3
141	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. <i>Blood</i> , <b>2018</b> , 132, 2861-2861	2.2	
140	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 2838-2838	2.2	
139	Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC. <i>European Radiology</i> , <b>2018</b> , 28, 736-746	8	14
138	Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. <i>Journal of Global Oncology</i> , <b>2018</b> , 4, 1-9	2.6	2
137	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1631-1641	2.2	448
136	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2845-2853	2.2	164
135	Line-Enhanced Deformable Registration of Pulmonary Computed Tomography Images Before and After Radiation Therapy With Radiation-Induced Fibrosis. <i>Technology in Cancer Research and Treatment</i> , <b>2018</b> , 17, 1533034617749419	2.7	2
134	-Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma. <i>Cancer Research</i> , <b>2018</b> , 78, 3445-3457	10.1	48
133	ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 833-842	8.9	55
132	Pulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lung. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 123, 270-275	5.3	2
131	Sinoatrial node toxicity after stereotactic ablative radiation therapy to lung tumors. <i>Practical Radiation Oncology</i> , <b>2017</b> , 7, e525-e529	2.8	2
130	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. <i>Blood</i> , <b>2017</b> , 130, 440-452	2.2	40
129	A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer. <i>Lung Cancer</i> , <b>2017</b> , 108, 173-182	5.9	8
128	Normal Tissue Constraints for Abdominal and Thoracic Stereotactic Body Radiotherapy. <i>Seminars in Radiation Oncology</i> , <b>2017</b> , 27, 197-208	5.5	45
127	Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. <i>Journal of Oncology</i> , <b>2017</b> , 2017, 4517834	4.5	16

126	Data normalization considerations for digital tumor dissection. <i>Genome Biology</i> , <b>2017</b> , 18, 128	18.3	23
125	Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes. <i>JCO Precision Oncology</i> , <b>2017</b> , 2017,	3.6	5
124	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 125, 338-343	5.3	22
123	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , <b>2017</b> , 7, 1394-1403	24.4	384
122	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. <i>Nature Genetics</i> , <b>2017</b> , 49, 1693-1704	36.3	289
121	Randomized Phase II Study of Preoperative Chemoradiotherapy [] Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1413-1420	8.9	19
120	Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1529-1537	13.4	255
119	A phase II randomized trial of Observation versus stereotactic ablative Radiation for OLigometastatic prostate CancEr (ORIOLE). <i>BMC Cancer</i> , <b>2017</b> , 17, 453	4.8	60
118	Practical workflow for rapid prototyping of radiation therapy positioning devices. <i>Practical Radiation Oncology</i> , <b>2017</b> , 7, 442-445	2.8	1
117	Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. <i>Cancer Discovery</i> , <b>2017</b> , 7, 86-101	24.4	159
116	Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA) <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3591-3591	2.2	15
115	Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. <i>Blood</i> , <b>2017</b> , 130, 826-826	2.2	3
114	Sinoatrial node dysfunction after stereotactic ablative radiation therapy in the chest <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 132-132	2.2	
113	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE) <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS5094-TPS5094	2.2	
112	Identification and genetic manipulation of human and mouse oesophageal stem cells. <i>Gut</i> , <b>2016</b> , 65, 1077-86	19.2	14
111	The impact of audiovisual biofeedback on 4D functional and anatomic imaging: Results of a lung cancer pilot study. <i>Radiotherapy and Oncology</i> , <b>2016</b> , 120, 267-72	5.3	7
110	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 364ra155	17.5	231
109	Control of inflammation by stromal Hedgehog pathway activation restrains colitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E7545-E7553	11.5	47

108	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , <b>2016</b> , 7, 11815	17.4	409
107	Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). <i>Radiotherapy and Oncology</i> , <b>2016</b> , 119, 454-60	5.3	19
106	Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors. <i>Radiation Oncology</i> , <b>2016</b> , 11, 40	4.2	3
105	Integrated digital error suppression for improved detection of circulating tumor DNA. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 547-555	44.5	589
104	Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 94, 808-15	4	25
103	Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, e17-21	4.9	9
102	Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1089-1089	2.2	7
101	Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA. <i>Blood</i> , <b>2016</b> , 128, 1752-1752	2.2	6
100	Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7511-7511	2.2	2
99	Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9000-9000	2.2	2
98	Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e20500-e20500	2.2	1
97	Noninvasive molecular subtyping and risk stratification of DLBCL <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7554-7554	2.2	1
96	Randomized phase II study of preoperative chemoradiotherapy (CRT)+/- Panitumumab (P) followed by consolidation chemotherapy (C) in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer (LANSCLC): Nrg oncology/RTOG 0839 <i>Journal of Clinical Oncology</i> , <b>2016</b> ,	2.2	
95	34, 8510-8510  Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma.  Blood, 2016, 128, 2930-2930	2.2	1
94	Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. <i>Blood</i> , <b>2016</b> , 128, 4107-4107	2.2	
93	Hypofractionated Intensity-Modulated Radiotherapy for Patients With Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, 588-594	4.9	12
92	Molecular profiling of single circulating tumor cells from lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E8379-E8386	11.5	79
91	Reprogramming the immunological microenvironment through radiation and targeting Axl. <i>Nature Communications</i> , <b>2016</b> , 7, 13898	17.4	97

# (2015-2016)

90	Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 95, 1504-1512	4	52
89	Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of (18)F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis. <i>Radiology</i> , <b>2016</b> , 281, 270-8	20.5	112
88	A 3-D Riesz-Covariance Texture Model for Prediction of Nodule Recurrence in Lung CT. <i>IEEE Transactions on Medical Imaging</i> , <b>2016</b> , 35, 2620-2630	11.7	24
87	Analysis of Long-Term 4-Dimensional Computed Tomography Regional Ventilation After Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 92, 683-90	4	13
86	Noninvasive pulmonary nodule elastometry by CT and deformable image registration. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 115, 35-40	5.3	6
85	Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. <i>Seminars in Radiation Oncology</i> , <b>2015</b> , 25, 305-12	5.5	74
84	The prognostic landscape of genes and infiltrating immune cells across human cancers. <i>Nature Medicine</i> , <b>2015</b> , 21, 938-945	50.5	1541
83	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. <i>Blood</i> , <b>2015</b> , 125, 3679-87	2.2	190
82	Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. <i>International Journal of Radiation Oncology</i> <i>Biology Physics</i> , <b>2015</b> , 92, 1044-1052	4	42
81	Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 1951-61	6.1	48
80	Robust enumeration of cell subsets from tissue expression profiles. <i>Nature Methods</i> , <b>2015</b> , 12, 453-7	21.6	3934
79	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 72-81	4	48
78	Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	43
77	Anatomic optimization of lung tumor stereotactic ablative radiation therapy. <i>Practical Radiation Oncology</i> , <b>2015</b> , 5, e607-13	2.8	3
76	Molecular determinants of radiation response in non-small cell lung cancer. <i>Seminars in Radiation Oncology</i> , <b>2015</b> , 25, 67-77	5.5	7
75	To SABR or not to SABR? Indications and contraindications for stereotactic ablative radiotherapy in the treatment of early-stage, oligometastatic, or oligoprogressive non-small cell lung cancer. <i>Seminars in Radiation Oncology</i> , <b>2015</b> , 25, 78-86	5.5	17
74	Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. <i>Lung Cancer</i> , <b>2015</b> , 89, 50-6	5.9	108
73	Outcomes of Modestly Hypofractionated Radiation for Lung Tumors: Pre- and Mid-Treatment Positron Emission Tomography-Computed Tomography Metrics as Prognostic Factors. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, 475-85	4.9	8

72	Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2015</b> , 126, 114-114	2.2	9
71	Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2015</b> , 126, 130-130	2.2	7
7º	Cancer Stem Cells and Tumor Radioresistance <b>2015</b> , 519-531		
69	Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL) <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8539-8539	2.2	
68	Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8570-8570	2.2	
67	Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. <i>Cancer Research</i> , <b>2014</b> , 74, 341-52	10.1	26
66	FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. <i>Bioinformatics</i> , <b>2014</b> , 30, 3390-3	7.2	130
65	Lung volume reduction after stereotactic ablative radiation therapy of lung tumors: potential application to emphysema. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 90, 216-23	4	5
64	Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5558-69	12.9	45
63	Pulmonary ventilation imaging based on 4-dimensional computed tomography: comparison with pulmonary function tests and SPECT ventilation images. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 90, 414-22	4	62
62	Targeting unique metabolic properties of breast tumor initiating cells. Stem Cells, 2014, 32, 1734-45	5.8	85
61	Vagal and recurrent laryngeal neuropathy following stereotactic ablative radiation therapy in the chest. <i>Practical Radiation Oncology</i> , <b>2014</b> , 4, 272-8	2.8	9
60	A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 88, 872-84	4	60
59	Imaging features associated with disease progression after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 294-301.e3	4.9	21
58	The effect of arm position on the dosimetry of thoracic stereotactic ablative radiation therapy using volumetric modulated arc therapy. <i>Practical Radiation Oncology</i> , <b>2014</b> , 4, 192-197	2.8	2
57	Lung Cancer Stem Cells and Resistance to Radiotherapy <b>2014</b> , 171-182		
56	Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. <i>Radiology</i> , <b>2014</b> , 270, 1-2	20.5	95
55	Feasibility and potential utility of multicomponent exhaled breath analysis for predicting development of radiation pneumonitis after stereotactic ablative radiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 957-964	8.9	6

## (2011-2014)

54	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. <i>Nature Medicine</i> , <b>2014</b> , 20, 548-54	50.5	1363
53	Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 553-63	15.9	42
52	Neurotrophic factor GDNF promotes survival of salivary stem cells. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 3364-77	15.9	71
51	Overcoming Radioresistance of Lung Cancer Stem Cells. Stem Cells and Cancer Stem Cells, 2014, 117-12	:7	2
50	Stem Cells, Cell Differentiation, and Cancer <b>2014</b> , 98-107.e3		1
49	Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8504-8504	2.2	
48	Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11016-11016	2.2	
47	Clinical impact of dose overestimation by effective path length calculation in stereotactic ablative radiation therapy of lung tumors. <i>Practical Radiation Oncology</i> , <b>2013</b> , 3, 294-300	2.8	19
46	Clinical implementation of intrafraction cone beam computed tomography imaging during lung tumor stereotactic ablative radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 87, 917-23	4	29
45	The Optimal Use of Radiotherapy in Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2013</b> , 11, 107-114	7.3	1
44	4D CT lung ventilation images are affected by the 4D CT sorting method. <i>Medical Physics</i> , <b>2013</b> , 40, 101	9 <b>.</b> д	45
43	Migration of implanted markers for image-guided lung tumor stereotactic ablative radiotherapy. Journal of Applied Clinical Medical Physics, <b>2013</b> , 14, 4046	2.3	17
42	Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1462-5	8.9	68
41	Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 84, 231-7	4	59
40	Intrafraction verification of gated RapidArc by using beam-level kilovoltage X-ray images. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, e709-15	4	23
39	Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. <i>Lung Cancer</i> , <b>2012</b> , 78, 219-24	5.9	40
38	Mechanisms of Radioresistance in Cancer Stem Cells <b>2011</b> , 345-360		
37	In Reply to Song et⊡al <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, 1194	4	

36	Reducing 4D CT artifacts using optimized sorting based on anatomic similarity. <i>Medical Physics</i> , <b>2011</b> , 38, 2424-9	4.4	21
35	Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 920-6	8.9	22
34	High retention and safety of percutaneously implanted endovascular embolization coils as fiducial markers for image-guided stereotactic ablative radiotherapy of pulmonary tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, 85-90	4	35
33	In Reply to Drs. Koch and Evans. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 80, 1605	4	
32	What the diagnostic radiologist needs to know about radiation oncology. <i>Radiology</i> , <b>2011</b> , 261, 30-44	20.5	17
31	The Myc connection: ES cells and cancer. <i>Cell</i> , <b>2010</b> , 143, 184-6	56.2	18
30	Metastatic cancer stem cells: an opportunity for improving cancer treatment?. <i>Cell Stem Cell</i> , <b>2010</b> , 6, 502-3	18	17
29	Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 78, 323-7	4	114
28	Therapeutic implications of the cancer stem cell hypothesis. <i>Seminars in Radiation Oncology</i> , <b>2009</b> , 19, 78-86	5.5	109
27	Association of reactive oxygen species levels and radioresistance in cancer stem cells. <i>Nature</i> , <b>2009</b> , 458, 780-3	50.4	1851
26	Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. <i>Cell</i> , <b>2009</b> , 138, 592-603	56.2	1010
25	Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.  Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5213-8	11.5	364
24	Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment. <i>Journal of Neuro-Oncology</i> , <b>2008</b> , 86, 133-41	4.8	41
23	Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. <i>Stem Cells</i> , <b>2008</b> , 26, 364-71	5.8	244
22	Cell-type specific gene expression profiles of leukocytes in human peripheral blood. <i>BMC Genomics</i> , <b>2006</b> , 7, 115	4.5	244
21	Genome-scale identification of membrane-associated human mRNAs. PLoS Genetics, 2006, 2, e11	6	76
20	Differential gene expression in anatomical compartments of the human eye. <i>Genome Biology</i> , <b>2005</b> , 6, R74	18.3	42
19	Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 5814-9	11.5	389

18	A method for detecting and correcting feature misidentification on expression microarrays. <i>BMC Genomics</i> , <b>2004</b> , 5, 64	4.5	11
17	Gene expression patterns in ovarian carcinomas. <i>Molecular Biology of the Cell</i> , <b>2003</b> , 14, 4376-86	3.5	273
16	T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression. <i>PLoS Biology</i> , <b>2003</b> , 1, E53	9.7	74
15	Individuality and variation in gene expression patterns in human blood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 1896-901	11.5	640
14	SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. <i>Nucleic Acids Research</i> , <b>2003</b> , 31, 219-23	20.1	325
13	Transcriptional response of human mast cells stimulated via the Fc(epsilon)RI and identification of mast cells as a source of IL-11. <i>BMC Immunology</i> , <b>2002</b> , 3, 5	3.7	45
12	Stereotyped and specific gene expression programs in human innate immune responses to bacteria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 972-	7 <sup>11.5</sup>	337
11	Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 8886-91	11.5	190
10	Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 11796-801	11.5	270
9	In vivo regulation of human skeletal muscle gene expression by thyroid hormone. <i>Genome Research</i> , <b>2002</b> , 12, 281-91	9.7	124
8	Transcriptional programs activated by exposure of human prostate cancer cells to androgen. <i>Genome Biology</i> , <b>2002</b> , 3, RESEARCH0032	18.3	140
7	Comparing functional genomic datasets: lessons from DNA microarray analyses of host-pathogen interactions. <i>Current Opinion in Microbiology</i> , <b>2001</b> , 4, 95-101	7.9	56
6	Large-scale identification of secreted and membrane-associated gene products using DNA microarrays. <i>Nature Genetics</i> , <b>2000</b> , 25, 58-62	36.3	213
5	Biochemical interactions integrating Itk with the T cell receptor-initiated signaling cascade. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 2219-30	5.4	217
4	Degradation of proteins from the ER of S. cerevisiae requires an intact unfolded protein response pathway. <i>Molecular Cell</i> , <b>2000</b> , 5, 729-35	17.6	164
3	Clinically-relevant cell type cross-talk identified from a human lung tumor microenvironment interactor	ne	1
2	A mathematical model of ctDNA shedding predicts tumor detection size		1
1	Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo		1